Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Aflibercept

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 4 (1)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07195344Phase 4Recruiting

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

NCT01843725Phase 1Completed

Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers

Showing all 2 trials

Research Network

Common Treatments

  • Aflibercept1
  • Capecitabine1
  • Trastuzumab Deruxtecan1
  • Pharmacokinetics Blood Samples1

Active Sponsors

  • Jules Bordet Institute1
  • Institut Claudius Regaud1
  • Ligue contre le cancer, France1
  • Oncopole Claudius Regaud1

Top Investigators

Related Conditions

  • Locally Advanced Or Metastatic Breast Cancers1
  • Metastatic Colorectal Cancers1
  • Metastatic Biliary Cancers1
  • Metastatic Oesophageal Cancers1
  • Metastatic Gastric Cancers1

Activity Timeline